2024-511647-25-00已完成4 期
Comparative Bioavailability of Cabozantinib Film-Coated Tablets in Healthy Participants Under Fasting Conditions
Bluepharma Industria Farmaceutica S.A.1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2024年9月13日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Medical Affairs Department
Scientific
Bluepharma Industria Farmaceutica S.A.
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Impact of pharmacokinetics of Cabozantinib on clinical response and adverse event in patients with hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000043775Juntendo University45
招募中
2 期
The pharmacological effects of using cabozantinib with a light breakfastrenal cell carcinomakidney cancer10038364NL-OMON53521eids Universitair Medisch Centrum12
进行中（未招募）
1 期
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.CTIS2024-511292-15-00Grupo Espanol De Tumores Neuroendocrinos41
进行中（未招募）
1 期
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo).Hepatocellular carcinoma (HCC)MedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002860-29-ITIRCCS ISTITUTO CLINICO HUMANITAS46
进行中（未招募）
1 期
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.MedDRA version: 21.0Level: PTClassification code: 10073251Term: Clear cell renal cell carcinoma Class: 100000004864CTIS2024-514058-59-00Fondazione IRCCS Istituto Nazionale Dei Tumori49